Abbott Laboratories News

A substantial recovery perspective has factored into the perception regarding the pharmaceutical industry, essentially due to a step away from the patent cliff and introduction of newer products by the pharmaceutical companies.

A live audio webcast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com . An archived edition of the presentation will be available later that day.

Top US stock recommendations of the day: ABBOTT LABORATORIES: Goldman Sachs upgrades to BUY from neutral.

Most of us go to the doctor for a checkup once per year. Many of us visit our dentists twice per year.

Abbott Laboratories : Jim Cramer ranked this stock a Buy . Cramer previously ranked this stock a Buy on February 7, 2013.

If I could send a message back in time to my younger self, I would only need to use four words, "Keep it simple, Stupid!" This is great advice for life in general, but especially good advice when investing one's own money.

This is the first Humira lawsuit filed against Abbott to go to trial. "We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney , Delores began experiencing chest pain and fevers.

Area companies have made the Fortune 500 list for 2013, including Abbott Laboratories and CDW.

Abbott today announced CE Marking for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.

Prior to the spinoff of Abbvie from Abbott Labs in early 2013 the joint company used to pay a pretty good dividend of 2.83% and post-split Abbott now pays a 1.52% yield while Abbvie pays a 3.58% yield.

Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand how it plays out into future stock price.

Nature , the world's premiere science journal, has finally caught on to what Rainbow Coral Corp.

's stock had its "outperform" rating reiterated by investment analysts at BMO Capital Markets in a note issued to investors on Friday, Analyst Ratings Network reports.

NestlA© USA and Mead Johnson Nutrition have dismissed calls to remove genetically-modified organisms ingredients from their infant formula products in the US - citing the approved use of GMOs by several national and global regulatory bodies.

Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand how it plays out into future stock price.

's stock had its "market perform" rating restated by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports.

The Supreme Court, last year, upheld the Affordable Care Act , which is the biggest overhaul of the healthcare industry in decades.

Yesterday was a big victory for Newton, Massachusetts,-based Galectin Therapeutics following new data that was presented by the company at the 2013 International Liver Congress in Amsterdam, The Netherlands.

Friday morning Covidien plc announced second quarter results for fiscal 2013 . Covidien shares plunged out of the gate to end the day down 6.58% to $62.00 . Given the fact that Covidien shares were trading at a fresh 52-week high of 68.83 just a dozen trading days earlier, is this dramatic decline in share price warranted? I don't think it is, as I ... (more)

An Abbott Laboratories shareholder proposal to remove genetically-modified organisms from its natural products - including its Similac infant formula range - has been rejected, the Illinois-based company has revealed.